Leerink Partners Increases Definium Therapeutics (NASDAQ:DFTX) Price Target to $30.00

Definium Therapeutics (NASDAQ:DFTX) had its target price upped by analysts at Leerink Partners from $23.00 to $30.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners’ target price would suggest a potential upside of 30.15% from the stock’s previous close.

Several other equities analysts have also issued reports on the company. JonesTrading assumed coverage on Definium Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective for the company. Jefferies Financial Group assumed coverage on Definium Therapeutics in a research report on Thursday, January 29th. They issued a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Definium Therapeutics in a research report on Monday, February 2nd. Robert W. Baird set a $37.00 price objective on Definium Therapeutics in a research report on Thursday, January 29th. Finally, Piper Sandler assumed coverage on Definium Therapeutics in a research report on Friday, April 10th. They issued an “overweight” rating and a $49.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Definium Therapeutics has an average rating of “Buy” and a consensus price target of $36.85.

Definium Therapeutics Trading Down 3.3%

Definium Therapeutics stock traded down $0.79 during midday trading on Wednesday, hitting $23.05. 483,700 shares of the stock were exchanged, compared to its average volume of 1,866,168. The company has a fifty day simple moving average of $18.89 and a two-hundred day simple moving average of $15.36. Definium Therapeutics has a 52 week low of $5.99 and a 52 week high of $26.25. The stock has a market capitalization of $2.30 billion, a PE ratio of -10.82 and a beta of 2.44. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12.

Hedge Funds Weigh In On Definium Therapeutics

A number of large investors have recently bought and sold shares of the company. Stoneridge Investment Partners LLC boosted its position in Definium Therapeutics by 7.5% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock worth $136,000 after acquiring an additional 804 shares during the last quarter. Cerity Partners LLC boosted its position in Definium Therapeutics by 2.4% during the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after acquiring an additional 1,165 shares during the last quarter. Creative Planning boosted its position in Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after acquiring an additional 1,655 shares during the last quarter. Rathbones Group PLC boosted its position in Definium Therapeutics by 7.1% during the 3rd quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock worth $356,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Bay Rivers Group boosted its position in Definium Therapeutics by 14.3% during the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.